The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...

CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.

The Centers for Medicare & Medicaid Services (CMS) finalized a Medicare Advantage (MA) rule proposed by the Biden ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The Biden administration had proposed late last year coverage of the popular medicines for obesity.

The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...